Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TTI2WET)

• DTT Name: Platelet-derived growth factor receptor (PDGFR)
• Synonyms: Platelet-derived growth factor receptor tyrosine kinase; PDGFR kinase; PDGF-R
• Gene Name: PDGFR
• DTT Type: Successful target; [1]
• UniProt ID: NOUNIPROTAC
• TTD ID: T52624

Molecular Interaction Atlas (MIA) of This DTT

5 Approved Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
CT-102	DMB8PF3	Diabetic foot ulcer	BD54	Approved	[2]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[1]
Intedanib	DMSTA36	Colorectal cancer	2B91.Z	Approved	[3]
Pazopanib HCl	DM6U9CQ	Renal cell carcinoma	2C90	Approved	[4]
Trapidil	DMY67U8	Acute coronary syndrome	BA41	Phase 4	[5]

4 Clinical Trial Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
TKI258	DMYLT67	Renal cell carcinoma	2C90	Phase 3	[1]
BAY-57-9352	DMVA5NS	Gastric adenocarcinoma	2B72	Phase 2	[1]
Vorolanib	DMIM1U9	Non-small-cell lung cancer	2C25	Phase 2	[6]
X-82	DMW1NKO	Age-related macular degeneration	9B75.0	Phase 2	[7]

2 Patented Agent(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PMID25623274-Compound-WO2014132220C1	DMA2IMQ	Pulmonary arterial hypertension	BB01.0	Patented	[8]
PMID25623274-Compound-WO2014132220C2	DMXEZWP	Pulmonary arterial hypertension	BB01.0	Patented	[8]

2 Discontinued Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Motesanib	DMZAL8C	Non-small-cell lung cancer	2C25.Y	Discontinued in Phase 3	[9]
CGP-53716	DMJ325M	Solid tumour/cancer	2A00-2F9Z	Terminated	[10]

1 Investigative Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PDGF gene therapy	DMSO3HM	Diabetic foot ulcer	BD54	Investigative	[2]

References

• [1] A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
• [2] Emerging drugs for diabetic foot ulcers. Expert Opin Emerg Drugs. 2006 Nov;11(4):709-24.
• [3] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [4] Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
• [5] Osteitis fibrosa is mediated by Platelet-Derived Growth Factor-A via a phosphoinositide 3-kinase-dependent signaling pathway in a rat model for chr... Endocrinology. 2008 Nov;149(11):5735-46.
• [6] Vorolanib, an oral VEGFR/PDGFR dual tyrosine kinase inhibitor for treatment of patients with advanced solid tumors: An open-label, phase I dose escalation and dose expansion trial. Chin J Cancer Res. 2021 Feb 28;33(1):103-114.
• [7] National Cancer Institute Drug Dictionary (drug id 695817).
• [8] Evaluation of WO-2014132220, selective PDGFR inhibitors for the treatment of pulmonary arterial hypertension.Expert Opin Ther Pat. 2015 Apr;25(4):493-9.
• [9] Clinical pipeline report, company report or official report of Amgen (2009).
• [10] Inhibition of cell growth: effects of the tyrosine kinase inhibitor CGP 53716. J Pharmacol Exp Ther. 1997 Oct;283(1):402-10.